In the study, people described both drug and NDE experiences that brought a more positive attitude to death, with less fear. People reported significant increases in psychological insight, welfare and meaning in their lives. ...

A single dose of the psychedelic drug psilocybin combined with supportive counseling leads to significant reductions in depressive symptoms, according to a new double-blind, placebo-controlled study. The findings have recently been published in eClinicalMedicine.…

Researchers in the United Kingdom studied whether the effects of psilocybin, a naturally occurring hallucinogenic drug, depend on the body mass index of the person, thereby requiring higher doses for the same effect in heavier people. The results showed that…

Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent...

Many doctors treat depression with SSRIs, but could psychedelic medication be more effective? A study published in BJ Psych Open suggests that psilocybin, a psychedelic substance found in "magic" mushrooms, may be more beneficial than certain antidepressants…

Membrane-permeable psychedelics promote cortical neuron growth by activating intracellular serotonin 2A receptors.

BackgroundPsychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SU...

Abstract Background and aims Although numerous cultures have used psychoactive substances for spiritual, or entheogenic, purposes, little is known about contemporary entheogenic spirituality, particularly outside of the few traditions that retain sacramental…

Patients tend to have a stronger brain response to music the day after receiving psilocybin-assisted therapy, according to new research published in the Journal of Affective Disorders. The stronger response to music was related to how intense the psychedelic…

The most comprehensive survey on psychedelic drug use to date has provided valuable insights into the frequency, reasons, and experiences associated with psychedelic use in Canada. The extensive findings, published in the journal Psychedelic Medicine, have…

Background: Psychedelic drugs have resurged in neuroscience and psychiatry with promising success in psychedelic-assisted therapy for the treatment of anxiety, depression, and addiction. At the cellular level, psychedelic drugs elicit neuroplastic processes…

Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggest that psiloc...

Translational Psychiatry - Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder

A recent study published in the Journal of Psychopharmacology suggests that psilocybin, the active component in "magic mushrooms", can induce lasting neuroplastic changes in the brain, which are associated with improvements in symptoms of depression. The…

A study revealed psilocybin diminishes the amygdala response to angry faces, potentially impacting emotion processing. This discovery underscores its potential for treating conditions like depression and anxiety, highlighting the profound effects of psychedelics…

Background and Purpose
Ayahuasca (AYA) is a botanical psychedelic with promising results in observational and small clinical trials for depression, trauma and drug use disorders. Its psychoactive ef...

Cellular and Molecular Life Sciences - Administration of multiple subanesthetic doses of ketamine increases the duration of antidepressant effects relative to a single ketamine dose, but the...

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

Translational Psychiatry - Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats